SpringWorks Therapeutics, Inc.
SWTXN/A
NASDAQBiotechnology🇺🇸North America
Drugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Jul 15, 2026
17wMarket Overview
Stock performance and key metrics
SWTX News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
Nirogacestat oral tablet
Desmoid Tumor
Mirdametinib (PD-0325901) oral capsule or dispersible tablet
Plexiform Neurofibroma
Nirogacestat
Ovarian Granulosa-Stromal Tumor
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Nirogacestat oral tablet | Phase 3 | Desmoid Tumor | - | - |
Mirdametinib (PD-0325901) oral capsule or dispersible tablet | Phase 2 | Plexiform Neurofibroma | - | - |
Nirogacestat | Phase 2 | Ovarian Granulosa-Stromal Tumor | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply